Incyte (MEX:INCY) EPS (Basic) : MXN1.35 (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Incyte EPS (Basic)?

Incyte's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was MXN10.83. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN1.35.

Incyte's EPS (Diluted) for the three months ended in Sep. 2024 was MXN10.63. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was MXN0.81.

Incyte's EPS without NRI for the three months ended in Sep. 2024 was MXN21.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was 16.34.

During the past 12 months, Incyte's average EPS without NRIGrowth Rate was -64.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Incyte's highest 3-Year average EPS without NRI Growth Rate was 152.30% per year. The lowest was -72.90% per year. And the median was 9.20% per year.

Incyte EPS (Basic) Historical Data

The historical data trend for Incyte's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte EPS (Basic) Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

39.23

-27.05

88.21

29.83

45.32

Incyte Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															13.24	15.28	12.61	-37.37	10.83

Incyte EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Incyte's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(10143.794	-	0)	/	223.628
	=	45.36

Incyte's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(2096.151	-	0)	/	192.629
	=	10.88

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.35

Incyte (MEX:INCY) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Incyte EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Incyte's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MEX:INCY) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy 0J9P:UK ICY:Germany ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.